Hello,
Welcome to Insider Healthcare. I'm healthcare editor Leah Rosenbaum, and this week in healthcare news:
If you're new to this newsletter, $4 Comments, tips? Email me at lrosenbaum@insider.com or tweet $4 Let's get to it...
Though the 2021 HLTH conference ended last week, our reporters are still bringing you news and interviews from those days in Boston.
This week, reporters Mohana Ravindranath and Shelby Livingston wrote about $4 between Highmark Health, an $18 billion healthcare system, and Verily. The two giant companies are partnering in an effort to increase value-based care.
Meanwhile reporter Andrew Dunn wrote about his interviews with $4, and why EQRx is Borisy's biggest venture yet.
Andrew also spoke to chief Regeneron scientist George Yancopoulos, $4 for all the CRISPR-based gene editing companies out there.
>$4
$4 $4Also at HLTH, reporter Megan Hernbroth spoke to institutional healthcare investors who $4 about the sudden increase of cash in the space from tech investors like Tiger Global Management.
They say that these massive influxes of cash are partially responsible for pushing company valuations to astronomically high levels.
Our reporters noted other new investment news this week. Mohana wrote about $4, even though it's a startup in the traditionally underfunded Medicaid sector.
And Lydia Ramsey Pflanzer and Blake Dodge reported on a startup geared towards $4.
This week, Andrew reported that an FDA advisory panel voted to recommend that the agency $4 While the FDA doesn't have to agree with its expert panel, the agency usually does.
